From Clinical Thyroidology® for the Public: Recently, more and more physicians have been preferring treating patients with Graves’ disease with methimazole with the goal to treat until a remission occurs. Recent studies have shown that patients are more likely to have a remission from Graves’ disease if they were on methimazole for a total of 60 months (long term) as compared to only 12-18 months (short term). This study was performed to assess predictors of relapse and to determine the rate of relapse of patients after short and long-term MMI therapy. Read More…
We welcome your feedback and suggestions. Let us know what you want to see in this publication.
Feedback & Suggestions
AMERICAN THYROID ASSOCIATION® , ATA® , THYROID® , CLINICAL THYROIDOLOGY® , and the distinctive circular logo are registered in the U.S. Patent and Trademark Office as trademarks of the American Thyroid Association® , Inc.